← Back to feed

Scancell Holdings

SCLP · AIM · Health Care · mcap £129m today

All announcements

All RNS · 23 Key events · 18

02 Oct 26

Notice of GM

Scancell Holdings plc (AIM: SCLP) ("Scancell", or the "Company"), a late-stage clinical immuno-oncology company developing active immunotherapies designed to enhance anti-tumor immune responses in difficult-to-treat cancers, announces that, further to its...
RNS 9803050 ↗
24 Sep 26

Scancell completes up to US$25m in debt financing

Scancell completes up to US$25 million in debt financing, providing optionality alongside equity investment to finance iSCIB1+ phase 3 development
RNS 9787943 ↗
03 Sep 26

Scancell to Present at the H.C. Wainwright Sept 26

Scancell Holdings plc (AIM: SCLP), a late-stage clinical immuno-oncology company developing active immunotherapies designed to enhance anti-tumor immune responses in difficult-to-treat cancers, announced today that company management will participate and...
RNS 9754612 ↗
19 Aug 26

ISCIB1+ MHRA CTA Approval for Ph3 trial

Scancell Receives UK MHRA Clinical Trial Authorization for the Phase 3 Registrational Trial of iSCIB1+ in Advanced Melanoma
RNS 9728522 ↗
06 Aug 26

Holding(s) in Company
RNS 9709085 ↗
31 Jul 26

Holding(s) in Company
RNS 9699437 ↗
31 Jul 26

Extension of Option Exercise Period

Extension of exercise period for CSO share options
RNS 9697129 ↗
28 Jul 26

Holding(s) in Company
RNS 9691990 ↗
27 Jul 26

Result of Retail Offer and Total Voting Rights

Result of Oversubscribed Retail Offer and Total Voting Rights
RNS 9687770 ↗
24 Jul 26

Merger and Financing

The following amendments have been made to the 'Merger and Financing' announcement released on 23 July 2026 at 08:05:45 under RNS No 5640N.
RNS 9686017 ↗
23 Jul 26

Oversubscribed UK Placing

596/2014 AS IT FORMS PART OF DOMESTIC LAW IN THE UNITED KINGDOM BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018 ("UK MAR").
RNS 9685020 ↗
23 Jul 26

Merger and Financing

596/2014 AS IT FORMS PART OF DOMESTIC LAW IN THE UNITED KINGDOM BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018 ("UK MAR").
RNS 9683817 ↗
23 Jul 26

Launch of Retail Offer

Retail Offer to raise up to £2.3 million (c.$3.0 million)
RNS 9683816 ↗
23 Jul 26

Proposed UK Placing

596/2014 AS IT FORMS PART OF DOMESTIC LAW IN THE UNITED KINGDOM BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018 ("UK MAR").
RNS 9683815 ↗
26 Jun 26

Response to Press Speculation

Scancell Holdings plc (AIM: SCLP) ("Scancell" or the "Company"), the developer of active immunotherapies to treat cancer, notes recent press speculation and confirms it is in advanced discussions with Neuphoria Therapeutics Inc.
RNS 9639823 ↗
28 Apr 26

FDA Fast Track Designation for iSCIB1+

Scancell receives FDA Fast Track Designation for iSCIB1+ in advanced melanoma and provides data update from its SCOPE Phase 2 study
RNS 9540643 ↗
02 Apr 26

CFO transition New CFO

David Schilansky to be appointed as financial advisor and interim CFO, bringing extensive industry and financial experience, including leading IPOs on Nasdaq and Euronext
RNS 9504434 ↗
29 Jan 26

Half-year Results

Interim Results for the six months ended 31 October 2025
RNS 9392529 ↗
26 Jan 26

FDA clearance of IND application for iSCIB1+

Scancell announces FDA clearance of IND application for global Phase 3 trial of iSCIB1+ in advanced melanoma
RNS 9385545 ↗
22 Jan 26

Notice of Results
RNS 9374569 ↗
09 Dec 25

Continued improvement in PFS with iSCIB1+

Scancell updated Phase 2 data shows continued improvement in progression free survival with iSCIB1+ in patients with first line advanced melanoma
RNS 9283697 ↗
07 Nov 25

Research Update

Scancell holds oral presentation of positive Phase 2 data on Immunobody® iSCIB1+ in late-stage melanoma at SITC 2025
RNS 9218344 ↗
30 Oct 25

Result of AGM
RNS 9204718 ↗

Source: Investegate RNS archive. Quotes are short extracts. Not investment advice.